Deferasirox Supplier in Kazakhstan
DEFRATAJ — WHO-GMP Deferasirox dispersible tablets, supplied direct from the manufacturer to NCEDS-registered importers.
Supply & Market
Taj Pharma supplies Deferasirox dispersible tablets to Kazakhstan as a WHO-GMP manufacturer with Russian, English and Cyrillic-labelled packaging options. DEFRATAJ reaches Taj Pharma India Ltd. through Saint-Petersburg and Vladivostok ports as well as overland routes via Kazakhstan, supporting hospital-tender and distributor channels.
The Kazakhstan market for iron-chelation therapy is driven by transfusion-dependent thalassemia, sickle-cell disease and myelodysplastic syndromes, where Deferasirox dispersible tablets are widely prescribed under the WHO Essential Medicines List.
Our regulatory and commercial team in Mumbai partners directly with importers, hospital procurement officers and Ministry-of-Health tender desks across Kazakhstan — from Astana to regional referral centres — for streamlined supply continuity.
Supply Capability for Kazakhstan
DEFRATAJ is supplied to Kazakhstan across all five strengths — 100 mg, 125 mg, 250 mg, 400 mg and 500 mg dispersible tablets — in HDPE bottles (30s/60s/100s) and Alu-Alu blister packs. Minimum-order quantities start at 50,000 tablets per strength with a typical lead time of 4–6 weeks from PO confirmation.
- Strengths shipped: 100 mg, 125 mg, 250 mg, 400 mg, 500 mg dispersible tablets
- Pack sizes: bottles (30/60/100 tabs), Alu-Alu blisters (10x10), hospital institutional packs
- MOQ: 50,000 tablets per strength per shipment (mixed pallets supported)
- Lead time: 4–6 weeks ex-Mumbai (JNPT / Nhava Sheva)
- Shelf life: 24 months at 25°C / 60% RH (Zone IVb stability data on file)
- Documents per shipment: CoA, CoO, packing list, invoice, BL/AWB, free-sale certificate
- Private label / co-branding: available with own artwork and brand registration
Cold-chain is not required for dispersible tablets, but climatised containers can be arranged on request for hot-route lanes into Kazakhstan.
Regulatory Pathway in Kazakhstan
Deferasirox dispersible tablets are registered in Kazakhstan with the National Center for Expertise of Medicines (NCEDS). Taj Pharma submits the full CTD dossier (Modules 1–5) along with our WHO-GMP certificate, CoPP, manufacturing licence, plant master file and validated stability data to NCEDS. Our regulatory desk handles queries, sample submissions and post-approval variations on behalf of local marketing-authorisation holders.
Local agent appointment, secondary packaging in Kazakh, Russian, and pharmacovigilance reporting are all coordinated from our Mumbai head office. Documentation can be couriered or e-submitted to NCEDS in Astana.
- CTD dossier (Modules 1–5) ready
- WHO-GMP · ISO 9001 · PIC/S-aligned plant
- CoPP & manufacturing licence on request
- Stability data (long-term & accelerated, Zone IVb)
- Country code
KZ· trade currency Kazakhstani Tenge